

Supplemental Digital Content 1: Demographic characteristics and adherence by indication for palivizumab prophylaxis

	NMD			χ^2	<i>p</i> value [‡]	SI <i>n</i> = 20,335	CMD <i>n</i> = 4,063	χ^2	<i>p</i> value ^{‡‡}
	Group 1 <i>n</i> = 498	Group 2 <i>n</i> = 107	Total NMD <i>n</i> = 605						
Enrolment age, months (median [IQR])	7.9 (3.1-16.8)	13.7 (5.1-23.8)	8.6 (3.3-18.3)	15.08	<0.0005	3.2 (1.5-5.7)	7.7 (3.1-14.3)	2,016.22	<0.0005
Gestational age, weeks (median [IQR])	37.2 (32.1-39.1)	38.1 (36.0-40.0)	37.7 (33.1-39.2)	10.66	0.001	31.9 (29.1-34.1)	37.9 (35.0-39.1)	4,055.57	<0.0005
Birth Weight, g (median [IQR])	2560 (1800-3235)	3000 (2450-3400)	2675 (1930-3300)	15.64	<0.0005	1633 (1165-2155)	2855 (2130-3323)	3,413.09	<0.0005
Enrolment weight, g (median [IQR])	6650 (4550-8950)	8700 (5840-11170)	7000 (4700-9300)	23.84	<0.0005	4000 (2800-5985)	7233 (4990-9290)	3,146.15	<0.0005
Male (%)*	268 (53.8)	67 (62.6)	335 (55.4)	2.76	0.097	11541 (56.8)	2207 (54.5)	7.86	0.020
Caucasian (%)	359 (72.1)	83 (77.6)	442 (73.1)	1.35	0.246	13760 (67.7)	2961 (72.9)	48.33	<0.0005
Daycare attendance	38	10	48	0.36	0.551	528	391	478.13	<0.0005

(%)*	(7.6)	(9.3)	(7.9)			(2.6)	(9.6)		
Siblings (%)*	301 (60.4)	66 (61.7)	367 (60.7)	0.06	0.812	12942 (63.6)	2670 (65.7)	9.13	0.010
Smoker at home (%)*	123 (24.7)	24 (22.4)	147 (24.3)	0.25	0.620	5557 (27.3)	895 (22.0)	50.35	<0.0005
>5 people in house (%)*	116 (23.3)	15 (14.0)	131 (21.7)	4.47	0.035	5049 (24.8)	865 (21.3)	25.30	<0.0005
Atopy in the family (%)*	217 (43.8)	49 (46.2)	266 (44.3)	0.20	0.653	8055 (39.8)	1713 (42.6)	15.18	0.001
Multiple births (%)*	52 (10.4)	2 (1.9)	54 (8.9)	7.96	0.005	6212 (30.5)	683 (16.8)	428.45	<0.0005
Adherence (%)*	331 (66.5)	64 (59.8)	395 (65.3)	1.72	0.190	13050 (64.2)	2786 (68.6)	28.68	<0.0005

‡ *p* values are specifically for comparisons between Group 1 and Group 2 NMD subjects

‡‡ *p* values are specifically for comparisons between Total NMD, SI and CMD groups

* Denotes variables that had a significant contribution to the Cox regression models

CMD, complex medical disorders; IQR, interquartile range; NMD, neurologic and muscular disorders; SI, standard indications